Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $328.13 +0.56%
Financial Fact:
Net income attributable to common shareowners: 37.74M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Net income attributable to common shareowners: 37.74M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Hudson Pacific Properties (HPP) Misses Q3 EPS by 265c
- Colliers International (CIGI) PT Lowered to $138 at BMO Capital
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
